ClinicalTrials.gg

Program

ruzaltatug rezetecan

Also written as “adebrelimab + SHR-A2009”, “almonertinib combined with SHR-A2009” and “SHR-A2009”.

In Jiangsu HengRui Medicine’s pipeline, HER3 ADC. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Nov 1, 20248 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine87 open or runningphase 3since Nov 1, 2024Oct 20, 2021Dec 2026phase 3 · NCT06671379
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-A2009, phase 4, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2021First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05114759 · 176 enrolled · China, Japan, South Korea
  2. May 24, 2022Phase 1 study in Advanced Solid TumorNCT05394818 · 19 enrolled · China
  3. Oct 8, 2023Phase 2 study in Advanced Solid TumorsNCT06092268 · 270 planned
  4. Dec 4, 2023Phase 2 study in Breast NeoplasmsNCT06222879 · 350 planned · China
  5. Nov 1, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06671379 · 498 enrolled · China
  6. Sep 12, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07183189 · 582 enrolled · China
  7. Sep 30, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07863167 · 660 planned · China
  8. Oct 19, 2026Phase 3 study in Non-squamous Non-small Cell Lung CancerNCT07895992 · 490 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06671379
  2. Dec 30, 2026Primary completion: phase 1 study in Advanced Solid TumorsNCT05114759
  3. Dec 30, 2028Primary completion: phase 3 study in Non-squamous Non-small Cell Lung CancerNCT07895992
  4. Dec 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07863167

TargetBeta

“HER3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of ruzaltatug, an immunoglobulin G1 (IgG1) human monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3), conjugated, via a cleavable peptide linker, to rezetecan, an exatecan derivative and cytotoxic DNA topoisomerase …”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of ruzaltatug, an immunoglobulin G1 (IgG1) human monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3), ”NCIt, by rule

Other programs on ERBB3

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
patritumab deruxtecanMerckphase 317
beruzatatug pelitecanruleMediLink Therapeutics (Suzhou)phase 39
JSKN016ruleAlphamab Oncologyphase 35
SYS6023ruleCSPC Pharmaceutical Groupphase 22
Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rulexadcera-biopharmaceutical-suzhou-co-ltdphase 21
Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rulehummingbird-biosciencephase 21
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
KHN922ruleChengdu Kanghong Pharmaceutical Groupphase 21
CS5007ruleCStone Pharmaceuticalsphase 11
JSKN016HCruleAlphamab Oncologyphase 11

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07895992Non-squamous Non-small Cell Lung Cancer · China3Not yet recruitingDec 30, 2028490
NCT07863167Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingDec 30, 2028660
NCT07183189Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingNov 2032582
NCT06671379Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingDec 2026498
NCT06222879Breast Neoplasms · China2RecruitingOct 31, 2026350
NCT06092268Advanced Solid Tumors2Not yet recruitingDec 2025270
NCT05394818Advanced Solid Tumor · China1CompletedApr 30, 202419
NCT05114759Advanced Solid Tumors · China, Japan, South Korea1Active, not recruitingDec 30, 2026176

How it is read

Names in the registry

  • “adebrelimab + SHR-A2009”, 3 entries
  • “almonertinib combined with SHR-A2009”, 2 entries
  • “SHR-A2009”, 2 entries
  • “SHR-A2009 + bevacizumab”, 1 entry
  • “SHR-A2009 combined with almonertinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.